These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 37880715)

  • 1. Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy.
    Bulliard Y; Andersson BS; Baysal MA; Damiano J; Tsimberidou AM
    J Hematol Oncol; 2023 Oct; 16(1):108. PubMed ID: 37880715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
    Yang Z; Wang Y
    Chin Med J (Engl); 2023 Oct; 136(19):2285-2296. PubMed ID: 37358555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering the next generation of CAR-NK immunotherapies.
    Biederstädt A; Rezvani K
    Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A metabolic switch to memory CAR T cells: Implications for cancer treatment.
    Rostamian H; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Pawelek JM; Hadjati J; Brown CE; Mirzaei HR
    Cancer Lett; 2021 Mar; 500():107-118. PubMed ID: 33290868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
    Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
    Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
    Ho M; Zanwar S; Paludo J
    Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies.
    Kampouri E; Little JS; Rejeski K; Manuel O; Hammond SP; Hill JA
    Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14157. PubMed ID: 37787373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exhaustion of CAR T cells: potential causes and solutions.
    Kouro T; Himuro H; Sasada T
    J Transl Med; 2022 May; 20(1):239. PubMed ID: 35606821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
    Gumber D; Wang LD
    EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic engineering for optimal chimeric antigen receptor T cell therapy.
    Ito Y; Kagoya Y
    Cancer Sci; 2022 Nov; 113(11):3664-3671. PubMed ID: 36000807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.
    Roselli E; Faramand R; Davila ML
    J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33463538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies.
    Zhang G; Deng L; Lu H; Zhang W
    Int J Clin Pharm; 2024 Feb; 46(1):186-194. PubMed ID: 38087131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
    Shen C; Zhang Z; Zhang Y
    Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of next-generation chimeric antigen receptor-engineered T-cell therapy].
    Kagoya Y
    Rinsho Ketsueki; 2022; 63(9):1290-1297. PubMed ID: 36198555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.
    Sun W; Liang AB; Huang H; Huang XJ
    Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy.
    Li W; Pan X; Chen L; Cui H; Mo S; Pan Y; Shen Y; Shi M; Wu J; Luo F; Liu J; Li N
    Front Immunol; 2023; 14():1186383. PubMed ID: 37342333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukapheresis for CAR-T cell production and therapy.
    Pessach I; Nagler A
    Transfus Apher Sci; 2023 Dec; 62(6):103828. PubMed ID: 37838564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
    Hill JA; Seo SK
    Blood; 2020 Aug; 136(8):925-935. PubMed ID: 32582924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.